secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-02-07T23:59:59+00:00
Accession:  0000318154-22-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)
-----------------------------------------------------------------------

- Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.
- GAAP EPS $3.36 (+22% Q4); full-year GAAP EPS $10.28 (-16%) due to $1.5B Five Prime IPR&D write-off.
- Non-GAAP EPS $4.36 Q4 (+26%), full-year $17.10 (+6%); non-GAAP operating margin 51.1%.
- Full-year free cash flow $8.4B, down from $9.9B due to 2020 swap monetization and capex timing.
- Quarterly dividend raised to $1.76/share, up 10% YoY (full-year $7.04, +10%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/0000318154-22-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/amgn-20220207.htm
  HTML page:      https://secwatch.observer/filing/0000318154-22-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer